Join us for an informative discussion on how COVID-19 has affected patient access to diagnoses, care, and innovative therapies. We’ve assembled an expert panel that will explore these important issues from an oncology perspective.  Our forum - moderated by Robert K. Coughlin, President & CEO of MassBio - will feature the following speakers:

• Dr. Meghan Mooradian, MD, Clinical Oncologist, Medical Oncology, Massachusetts General Hospital
• Kirsten Sloan, Managing Director, Policy, American Cancer Society’s Cancer Action Network (ACS CAN)
• Michelle Carrillo, Director, Advocacy Relations-Oncology, Amgen

The COVID-19 pandemic has had a profound, direct impact on Massachusetts, with over 121,000 total cases-to-date. However, as response and recovery continue, the ripple effects reveal a much broader public health impact. Our health care system has been shaken to its core, perhaps none more than the area of cancer care.

An American Cancer Society Cancer Action Network (ACS CAN) survey of cancer patients and survivors focused on COVID-19 effects uncovered that of those in active treatment, 79% reported delays to their health care. What does the patient’s path to diagnosis and treatment look like? Has cancer care adapted to meet these challenges? How is Massachusetts uniquely positioned to meet the moment? Our panel of experts will address these questions and more from their patient, oncologist, and innovator perspectives.

MassBio makes every effort to accommodate our entire community at each of our events. Please let us know at least 3 days in advance of the event if you require special accommodations, such as captioning.

This event is supported by Amgen